Pancreatic Cancer Research

ResearcherHarvard UniversityActive in the last 2 years

Xiawei Li

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-2709-7020; OpenAlex author ID A5102833206. Sources: OpenAlex.

Their work

Papers
9 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
16
Papers, trials and grants by year

2021: 2 papers · 2022: 2 papers · 2023: 1 paper · 2024: 3 papers · 2025: 1 paper

Papers 9

  1. Unraveling the Role of MDK-SDC4 Interaction in Pancreatic Cancer-Associated New-Onset Diabetes by Single-Cell Transcriptomic Analysis. Co-author DOI 10.1002/advs.202409987↗
  2. Predicting Pancreatic Cancer in New-Onset Diabetes Cohort Using a Novel Model With Integrated Clinical and Genetic Indicators: A Large-Scale Prospective Cohort… Co-author DOI 10.1002/cam4.70388↗
  3. Sorcin can trigger pancreatic cancer-associated new-onset diabetes through the secretion of inflammatory cytokines such as serpin E1 and CCL5. First author DOI 10.1038/s12276-024-01346-4↗
  4. Author Correction: Sorcin can trigger pancreatic cancer-associated new-onset diabetes through the secretion of inflammatory cytokines such as serpin E1 and CCL… First author DOI 10.1038/s12276-024-01363-3↗
  5. Prediction of risk and overall survival of pancreatic cancer from blood soluble immune checkpoint-related proteins. Co-author DOI 10.3389/fimmu.2023.1189161↗
  6. Preoperative recurrence prediction in pancreatic ductal adenocarcinoma after radical resection using radiomics of diagnostic computed tomography. Co-author DOI 10.1016/j.eclinm.2021.101215↗
  7. Efficacy and safety of FOLFIRINOX as second-line chemotherapy for advanced pancreatic cancer after gemcitabine-based therapy: A systematic review and meta-anal… Co-author DOI 10.1177/03000605221093225↗
  8. Multi-institutional development and external validation of machine learning-based models to predict relapse risk of pancreatic ductal adenocarcinoma after radi… Co-author DOI 10.1186/s12967-021-02955-7↗
  9. Whether early stage pancreatic ductal adenocarcinoma patients could benefit from the post-operation chemotherapy regimens: a SEER-based propensity score matchi… First author DOI 10.3724/zdxbyxb-2021-0194↗

Closest collaborators

The 16 strongest of 16 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yulian Wu · 8 shared papers, 2021–2025 · strength 1.47
  2. Zengyu Feng · 3 shared papers, 2024–2025 · strength 0.61
  3. Jiali Gong · 3 shared papers, 2024–2025 · strength 0.61
  4. Yongji Sun · 3 shared papers, 2024 · strength 0.53
  5. Hongxia Xu · 3 shared papers, 2024 · strength 0.53
  6. Yiqun Fan · 3 shared papers, 2021–2024 · strength 0.46
  7. Qiaojun He · 2 shared papers, 2024 · strength 0.34
  8. Yizhao Zhou · 2 shared papers, 2024 · strength 0.34
  9. Kezhong Tang · 1 shared paper, 2022 · strength 0.22
  10. Wenjie Lu · 1 shared paper, 2022 · strength 0.22
  11. Lantian Wang · 1 shared paper, 2022 · strength 0.22
  12. Jinbo SHI · 1 shared paper, 2021 · strength 0.22
  13. Xifeng Wu · 1 shared paper, 2023 · strength 0.17
  14. Xin Dong · 1 shared paper, 2023 · strength 0.17
  15. Sai Pan · 1 shared paper, 2023 · strength 0.17
  16. Tianye Niu · 1 shared paper, 2022 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.